2025-03-28T12:10:59-04:00 2024-05-31 870516083 LARSON & COMPANY PC 11240 S RIVER HEIGHTS DR STE 300 SOUTH JORDAN UT 840955123 990 2023-06-01 880189404 NEVADA CANCER RESEARCH FOUNDATION INC NEVA 7023840013 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 SHANNON YULE PROGRAM ADMINISTRATO 7023840013 2025-03-24 true false RICHARD SCORESBY CPA P00573067 8013131900 2025-03-24 2023 2025-03-06 01:10:19Z SHANNON YULE 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 2123807 false X SNCRF.ORG X 1983 NV CANCER RESEARCH. 3 2 34 1 0 1934913 1835413 485198 278133 5669 9956 305 2425780 2123807 0 0 1686509 1747907 0 0 823686 488745 2510195 2236652 -84415 -112845 1774824 1585987 762118 686126 1012706 899861 CANCER RESEARCH. false false 1657671 80429 COOPERATIVE GROUP ONCOLOGY TRIALS: PATIENTS WERE TREATED IN CORRELATION WITH VARIOUS RESEARCH PROGRAMS WITH FOLLOW-UP AND SUBMISSION DATA ON 325 PATIENTS FOR NCA TRIALS. 143265 197704 INDUSTRY SPONSOR TRIALS: NO PATIENTS WERE TREATED USING VARIOUS CANCER- RELATED PHARMACEUTICALS TRIALS. 1800936 true true false false false false false false false false true false false true true true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 3 0 true 34 true false false false false false false false false false false false false X 3 2 false false false false false false false true true false false true true true true true true true false false X SHANNON YULE 7023840013 1750 E DESERT INN ROAD STE 200 LAS VEGAS NV 89169 SHANNON YULE PROGRAM ADMI 40.00 X 109171 0 16219 JOHN ELLERTON MD PRESIDENT 3.00 X X 51250 0 0 BRUCE BORGELT MD DIRECTOR 1.00 X 0 0 0 JIM CHRISTENSON MD SECRETARY 0.00 X X 0 0 0 160421 16219 1 false false false 1820248 15165 1835413 PHARMACEUTICAL TRIALS 541700 197704 197704 CANCER RESEARCH TRIALS 541700 80429 80429 278133 9956 9956 MICELLANEOUS REVENUE 900099 305 305 305 2123807 278438 9956 197417 161148 36269 1310402 1065751 244651 130668 112170 18498 109420 93930 15490 20366 15478 4888 132813 129438 3375 1393 1383 10 67502 32035 35467 84660 61847 22813 39883 34472 5411 1946 1946 25263 25263 2196 1669 527 LAB FEES & PATIENT COSTS 53117 53117 PROGRAM SUPPLIES 30835 24641 6194 BAD DEBT EXPENSE 12611 12611 EQUIPMENT RENTAL & LEASE 12420 10418 2002 3740 3439 301 2236652 1800936 435716 0 167168 211416 240114 212439 657246 461817 22118 24175 228892 191163 47424 37729 55671 74852 585083 563559 1774824 1585987 162470 600141 599648 85985 762118 686126 X 1012706 899861 1012706 899861 1774824 1585987 X -112845 X false true X true true true X 1102185 1769205 2412271 1934913 1835414 9053988 1102185 1769205 2412271 1934913 1835414 9053988 9053988 993 1346 5669 9955 17963 9071951 1039679 0.99800 0.99890 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 39111 13891 25220 189781 177272 12509 37729 RIGHT-OF-USE ASSET 563559 563559 LEASE LIABILITY 85985 85985 X 2339696 228500 228500 2111196 12611 12611 2123807 2452541 228500 228500 2224041 12611 12611 2236652 SCHEDULE D, PAGE 3, PART X BECAUSE THERE ARE NO KNOWN CIRCUMSTANCES THAT WOULD PLACE THE FOUNDATION'S STATUS AS A TAX-EXEMPT ORGANIZATION IN JEOPARDY, AND BECAUSE THE FOUNDATION DOES NOT ENGAGE IN UNRELATED BUSINESS INCOME ACTIVITIES, AND THERE ARE NO KNOWN UNCERTAIN TAX POSITIONS TAKEN OR TO BE TAKEN, NO PROVISION HAS BEEN MADE FOR INCOME TAXES. IN THE UNLIKELY EVENT ANY INCOME TAXES OR TAX- RELATED PENALTIES AND INTEREST ARE ASSESSED, SUCH ITEMS WOULD BE RECORDED AS GENERAL AND ADMINISTRATION EXPENSES. THE FOUNDATION'S RETURNS OF ORGANIZATION EXEMPT FROM INCOME TAX (FORM 990) GENERALLY REMAIN SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE FOR THREE YEARS AFTER THEY ARE FILED. SCHEDULE D, PAGE 4, PART XI, LINE 4B BAD DEBT EXPENSE 12,611 SCHEDULE D, PAGE 4, PART XII, LINE 4B BAD DEBT EXPENSE 12,611 FORM 990, PAGE 6, PART VI, LINE 11B THE PROGRAM ADMINISTRATOR, ASSOCIATE PROGRAM ADMINISTRATOR, AND THE PRINCIPAL INVESTIGATOR WILL REVIEW FORM 990 AND DISCUSS WITH EACH OTHER ANY QUESTIONS AND/OR COMMENTS. THE PROGRAM ADMINISTRATOR WILL DIRECT THESE QUESTIONS TO THE TAX PREPARER AND RELAY THE ANSWERS TO THE ASSOCIATE PROGRAM ADMINISTRATOR AND PRINCIPAL INVESTIGATOR. IF THEY ARE SATISFIED WITH THE RESPONSES, NO FURTHER ACTION WILL BE REQUIRED. IF THEY ARE NOT SATISFIED, THEN A MEETING WILL BE SCHEDULED TO DISCUSS THE OUTSTANDING QUESTIONS WITH THE TAX RETURN PREPARER. FORM 990, PAGE 6, PART VI, LINE 12C ALL INVESTIGATORS WHO PARTICIPATE IN CLINICAL TRIALS ARE REQUIRED TO COMPLETE A FORM FDA 1572 ANNUALLY AND SUBMIT IT TO THE FOOD & DRUG ADMINISTRATION (FDA). THE FORM FDA 1572 IS A STATEMENT OF INVESTIGATOR (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312). IT INCLUDES A SUBPART, FINANCIAL DISCLOSURE FORM, WHICH THE INVESTIGATOR MUST ALSO COMPLETE ANNUALLY. IN ADDITION TO COMPLETING THE FORM FDA 1572, INVESTIGATOR AND FOUNDATION STAFF MUST ALSO COMPLETE AN ANNUAL FINANCIAL CONFLICT OF INTEREST DISCLOSURE FORM. THE POLICY AND PROCEDURES FOLLOWED BY THE FOUNDATION ARE INTENDED TO MEET THE MOST RECENT REQUIREMENTS PUBLISHED BY THE FEDERAL GOVERNMENT REGARDING REVISED FINANCIAL CONFLICT OF INTEREST (FCOI) REGULATION, PROMOTING OBJECTIVITY IN RESEARCH ON AUGUST 25, 2011 (42 CFR PART 50 SUBPART F AND 45 CFT PART 94). THE FOUNDATION WILL REPORT SIGNIFICANT FINANCIAL CONFLICTS OF INTEREST AS OUTLINED IN THE FEDERAL REGULATIONS. FORM 990, PAGE 6, PART VI, LINE 15A THE FOUNDATION USES DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS AT SIMILAR ORGANIZATIONS. FOUNDATION EMPLOYEES ARE EVALUATED ANNUALLY AND THE RATE OF PAY IS DISCUSSED DURING THE EVALUATION AND IS WRITTEN AS PART OF THE EVALUATION PROCESS. THESE ARE THE RECORDS WITH RESPECT TO THE DECISIONS REGARDING THE COMPENSATION PROCESS. THE PRINCIPAL INVESTIGATOR IS COMPENSATED PER FEDERAL GUIDELINES. NONE OF THE OTHER TRUSTEES RECEIVE COMPENSATION. FORM 990, PAGE 6, PART VI, LINE 19 IF A REQUEST IS MADE, THE PROGRAM ADMINISTRATOR, AFTER CONSULTATION WITH THE PRINCIPAL INVESTIGATOR, RESPONDS. FORM 990, PART XI, LINE 9 BAD DEBT EXPENSE -12,611 BAD DEBT EXPENSE 12,611